Skip to content
PIL Logo

Abilify 7.5 mg/ml solution for injection (intramuscular)

Last Updated on eMC 15-Nov-2016 View document  | Otsuka Pharmaceuticals (UK) Ltd Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 15-Nov-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - date of revision

Updated on 12-Jul-2016 and displayed until 15-Nov-2016

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 05-Oct-2015 and displayed until 12-Jul-2016

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 14-May-2015 and displayed until 05-Oct-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 07-Nov-2014 and displayed until 14-May-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 14-Aug-2014 and displayed until 07-Nov-2014

Reasons for adding or updating:

  • Change to section 1 - what the product is
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 5 - how to store
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 03-Jan-2014 and displayed until 14-Aug-2014

Reasons for adding or updating:

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 19-Sep-2013 and displayed until 03-Jan-2014

Reasons for adding or updating:

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects

Updated on 08-Apr-2013 and displayed until 19-Sep-2013

Reasons for adding or updating:

  • Improved presentation of PIL

Updated on 03-Apr-2013 and displayed until 08-Apr-2013

Reasons for adding or updating:

  • Change to section 6 - date of revision

Updated on 15-Feb-2013 and displayed until 03-Apr-2013

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 06-Feb-2013 and displayed until 15-Feb-2013

Reasons for adding or updating:

  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 03-Dec-2012 and displayed until 06-Feb-2013

Reasons for adding or updating:

  • Change to how the medicine works
  • Change to date of revision

Updated on 31-Jul-2012 and displayed until 03-Dec-2012

Reasons for adding or updating:

  • Improved Electronic Presentation
  • Updates to formatting

Updated on 07-Oct-2011 and displayed until 31-Jul-2012

Reasons for adding or updating:

  • Change to information about pregnancy or lactation

Updated on 02-Feb-2011 and displayed until 07-Oct-2011

Reasons for adding or updating:

  • Change to MA holder contact details

Updated on 22-Dec-2010 and displayed until 02-Feb-2011

Reasons for adding or updating:

  • Change to, or new, use for medicine

Updated on 02-Feb-2010 and displayed until 22-Dec-2010

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 21-Dec-2009 and displayed until 02-Feb-2010

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 09-Jun-2009 and displayed until 21-Dec-2009

Reasons for adding or updating:

  • Improved Electronic Presentation
  • Change to date of revision

Updated on 24-Jun-2008 and displayed until 09-Jun-2009

Reasons for adding or updating:

  • Changes to therapeutic indications
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to side-effects

Updated on 25-Apr-2008 and displayed until 24-Jun-2008

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Otsuka Pharmaceuticals (UK) Ltd

Company image
Address

Gallions, Wexham Springs, Framewood Road, Wexham, SL3 6PJ, UK

Fax

+44 (0)20 8848 0529

Telephone

+44 (0)20 3747 5300

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

aripiprazole

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue